Endocrine Abstracts

Background: Children with pre-symptomatic type 1 diabetes (T1D) can be identified through testing for circulating islet autoantibodies (AAb). Identifying children at risk reduces diabetic ketoacidosis at onset and allows participation in trials aiming to delay disease onset. Teplizumab is the first immunomodulatory agent licensed in the US to delay the onset of T1D by 3 years in individuals at risk; a licensing decision is awaited in the UK. The EarLy Surveill...